Monitoring kidney cancer using blood tests for DNA changes
Official title: Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
Run by Jinling Hospital, China · NCT05917106 · Data updated 2026-11-12
This study is testing if blood tests that look for DNA changes can help track kidney cancer in patients before and after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 450 (estimated) |
| Sponsor | Jinling Hospital, China Academic / other |
| Locations | 1 site (Nanjing, Jiangsu) |
| Status | Recruiting |
| Started | December 26, 2022 |
| Main results expected | June 2028 |
| Study ends | June 2030 |
| Registry record updated | December 11, 2025 |
| Trial ID | NCT05917106 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients newly diagnosed with renal cell carcinoma who have not received any prior treatment and are eligible for radical surgical intervention.
✕Probably not a fit
Patients with other cancers, those who have received prior antitumor therapy, or individuals with uncontrolled heart conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of circulating tumor DNA (ctDNA) and its methylation patterns in monitoring patients with renal cell carcinoma before and after surgery. It will analyze changes in ctDNA levels and methylation status over time, comparing these findings with traditional imaging and blood tumor markers. The goal is to establish a reliable method for tracking kidney cancer progression and treatment response through non-invasive blood tests.
Why it matters
Potential benefit: If successful, this approach could provide a more accurate and less invasive method for monitoring kidney cancer, improving patient outcomes.
How similar studies have gone: While some studies have explored ctDNA in cancer monitoring, this specific focus on ctDNA methylation in renal cancer is novel and has not been extensively tested in large cohorts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed renal cell carcinoma * Without any treatment * Agree and accept radical surgical treatment * Signed written informed consent * ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1 * Follow up protocol and related procedures Exclusion Criteria: * Had other cancers * Had received any antitumor therapy before * Known or suspected active autoimmune disease * Informed consent is not possible due to medical or psychiatric problems * Have clinical symptoms or diseases of the heart that are not well controlled * Patients judged by the investigators to be unsuitable for inclusion in this study
Where it's running
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Nanjing, Jiangsu, China Recruiting
Study contacts
- Study coordinator: Le Qe, M.D.
- Email: septsoul@hotmail.com
- Phone: 15720625951
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR
This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.
-
Using a digital tool to improve kidney surgery planning
This study is testing a new digital tool to see if it helps doctors plan kidney surgery better for patients with localized kidney cancer compared to just using regular CT scans.
-
Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home
This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.
-
Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer
This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.
-
NEO-811 for advanced or metastatic clear cell kidney cancer
This study will try the experimental oral drug NEO-811 in people with locally advanced or metastatic clear cell kidney cancer who have progressed on or refused standard treatments.
-
Combining sasanlimab, palbociclib, and axitinib for metastatic kidney cancer
This test tries a combination of sasanlimab, palbociclib, and axitinib in people with advanced or metastatic clear cell or translocation renal cell carcinoma to see if it works and is safe.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.